How a nasal vaccine could reduce the risk of COVID infections — and new variants

Written By Bluelake Biotechnology

https://www.marketwatch.com/story/why-a-nasal-vaccine-could-reduce-the-risk-of-covid-infections-and-new-variants-e68a284b

Bluelake Biotechnology
Previous

Blue Lake Biotechnology to Be Featured at the Biotechnology Innovation Organization (BIO) International Convention
Next

Nasal Covid vaccine shows promise in early clinical trial